PTGX FY 2025 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M-89.4% YoY

Gross Profit

$45M97.3% margin

Operating Income

-$158M-343.6% margin

Net Income

-$130M-282.8% margin

EPS (Diluted)

$-2.05

Cash Flow

Operating Cash Flow

$58M

Free Cash Flow

$56M

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$670M

Total Liabilities

$55M

Stockholders' Equity

$615M

Cash & Equivalents

$128M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$434M	-89.4%
Gross Profit	$45M	$434M	-89.7%
Operating Income	-$158M	$253M	-162.5%
Net Income	-$130M	$275M	-147.3%